Goal-directed therapy is not as simple as it seems.
J Bone Miner Res 2026 May 12. [Online ahead of print]

Abstract

A case is discussed of a postmenopausal woman started on alendronate treatment based on a low T-score in the total hip. 3 yr later, her total hip score remains below -2.5, the target set by the ASBMR task force on goal-directed therapy.(1) The important question at this juncture is whether she should change to a different treatment that might result in better improvement in total hip BMD or if she should continue treatment with alendronate.

Authors+Show Affiliations

Watts NB0000-0003-0719-9801Mercy Health Osteoporosis and Bone Health Services, 4760 East Galbraith Road, Suite 212, Cincinnati OH 45236.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

42119022